- Home
- BORR vs AKBA Comparison
BORR vs AKBA Comparison
Compare BORR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- AKBA
- Stock Information
- Founded
- BORR 2016
- AKBA 2007
- Country
- BORR Bermuda
- AKBA United States
- Employees
- BORR N/A
- AKBA N/A
- Industry
- BORR Oil & Gas Production
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- AKBA Health Care
- Exchange
- BORR Nasdaq
- AKBA Nasdaq
- Market Cap
- BORR 870.1M
- AKBA 729.1M
- IPO Year
- BORR 2019
- AKBA 2014
- Fundamental
- Price
- BORR $3.07
- AKBA $2.31
- Analyst Decision
- BORR Hold
- AKBA Strong Buy
- Analyst Count
- BORR 2
- AKBA 5
- Target Price
- BORR $3.25
- AKBA $6.90
- AVG Volume (30 Days)
- BORR 4.5M
- AKBA 2.6M
- Earning Date
- BORR 11-05-2025
- AKBA 11-06-2025
- Dividend Yield
- BORR 1.35%
- AKBA N/A
- EPS Growth
- BORR N/A
- AKBA N/A
- EPS
- BORR 0.20
- AKBA N/A
- Revenue
- BORR $989,000,000.00
- AKBA $203,733,000.00
- Revenue This Year
- BORR $0.04
- AKBA $43.91
- Revenue Next Year
- BORR N/A
- AKBA $32.09
- P/E Ratio
- BORR $15.82
- AKBA N/A
- Revenue Growth
- BORR 7.73
- AKBA 16.75
- 52 Week Low
- BORR $1.55
- AKBA $1.52
- 52 Week High
- BORR $4.47
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- BORR 58.17
- AKBA 31.66
- Support Level
- BORR $2.91
- AKBA $2.93
- Resistance Level
- BORR $3.19
- AKBA $3.19
- Average True Range (ATR)
- BORR 0.15
- AKBA 0.14
- MACD
- BORR 0.04
- AKBA -0.02
- Stochastic Oscillator
- BORR 82.32
- AKBA 20.19
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.